package R, to analyze the relationships between cognitive assessment results and clinical characteristics, and Kappa test was used to analyze the consistency of physical examination and cognitive scales for assessing the neurocognitive functions in patients. Finally, the related factors were analyzed with univariate and multivariate analysis. Results: Clinical physical examination showed that there were 21 cases of cognitive decline (28.4%) and 53 cases of normal cognition (71.6%), while the results of cognitive scales revealed that there were 6 cases of normal cognition (8.1%), 26 cases of mild impairment (35.1%), 2 cases of moderate impairment (2.7%) and 40 cases of severe impairment (54.1%). The result of Kappa test showed Kappa<0.4, indicating that the differences between cognitive scale results and physical examination were significant. The univariate analysis on the factors related to neurocognitive function impairment revealed that the risk factors that may affect the degree of neurocognitive function impairment included age, KPS score, GPA score, RPA class and the number of metastatic tumors; and the multivariate analysis showed that age and RPA class>2 were the independent risk factors for neurocognitive function impairment. Background: Interstitial lung diseases (ILD) frequently occur in patients with lung cancer. The optimal treatment strategy for non-smallcell lung cancer (NSCLC) patients with ILD remains unclear. We reviewed the efficacy and safety of surgery, chemotherapy, and radiotherapy. Method: We analyzed the medical records of patients with clinical stage IIIA-N2 NSCLC with ILD who were treated at our hospital between 2001 and 2016. Results: 505 patients with clinical stage IIIA-N2 NSCLC were included. Of these patients with ILD, treatments included surgical resection (S) in 14 patients, chemoradiotherapy (CRT) in 7 patients, palliative chemotherapy (C) in 7 patients and palliative radiotherapy in one patient. The median follow-up period was 38 months. The patients' characteristics were as follows S/CRT/C: male, 26/6/7 patients; median age (range), 69 (58-82)/69 (60-75)/69 (35-82) years. Of the S, pathological stage IA/IIA/IIB/IIIA/IIIB, 1/1/2/ 9/1 patients. The median progression-free survival times were 9.5 months (95% CI: 5.3-45.3 months) in S, 45.9 months (95% CI: 7.2 months-not reached [NR]) in CRT, and 5.0 months (95% CI: 0.5-10.5 months) in C. The median overall survival time were 33.3 months (95% CI: 9.8 months-NR) in S, 45.9 months (95% CI: 8.3 months-NR) in CRT, and 9.9 months (95% CI: 1.6-42.4 months) in C. One patient died within 1 month of surgical resection. Acute exacerbations of ILD (AE-ILD) were noted in 14 % of the patients; 3 patients after surgery and 1 patient after chemoradiotherapy. Conclusion: The surgery and chemoradiotherapy can be considered as a treatment option for selected patients with IIIA-N2 NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits. Keywords: interstitial lung diseases, stage IIIA, nsclc Background: Leptomeningeal metastasis (LM) occurs in 3%-5% of patients with advanced non-small-cell lung cancer (NSCLC). However, its incidence has increased in patients with driver gene mutations owing to their prolonged survival from target therapies. The prognosis of NSCLC patients with LM has improved to 3-11months in the era of precision medicine. Understanding how prognosis varies across this heterogeneous patient population is essential to individualize care and design future clinical trials. Method: We retrospectively reviewed the medical records of 301 lung cancer patients, who were diagnosed as LM by brain MRI or cytology or next-generation sequencing of cerebrospinal fluid between January 2011 and April 2018. Their clinicopathological characteristics and prognostic data were analyzed. All prognostic factors were weighted for significance by hazard ratios (HR). Results: Among the 301 patients, the median age was 55 years (26-86). Most of them were adenocarcinoma (96.3%，290/301). There were 149 males and 152 females. The median overall survival of the 301 patients was 7.1 months from LM diagnosis. Multivariate analysis revealed that KPS score <60 (HR, 4.30, 3.15-5.87), presence of extracranial metastases (ECM) (HR, 1.79, 1.27-2.52), EGFR negative or unknown and ALK negative or unknown (HR, 1.83, 1.27-2.62) were the independent prognostic factors for poor overall survival. Based on the HR, we made a novel molGPA scoring criteria for LM modified from the molGPA for brain metastasis (BM) and developed a novel molGPA model stratified patients into three categories. The median overall survival for patients with the novel molGPA scores of 0, 0.5-1.0, and1.5-2.0 was 0.3, 4.2, and 12.8 months, respectively (p < 0.001). The C-index of this model was 0.69 (95%CI: 0.65-0.72). Conclusion: We developed a novel molGPA model, which could help clinicians to stratify lung cancer patients with LM in the era of precision medicine. Further research is needed to validate and improve this model.
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